588,400 Shares in Roivant Sciences Ltd. $ROIV Acquired by ING Groep NV

ING Groep NV purchased a new position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) in the 4th quarter, HoldingsChannel.com reports. The fund purchased 588,400 shares of the company’s stock, valued at approximately $12,768,000.

Several other hedge funds have also added to or reduced their stakes in ROIV. Goldman Sachs Group Inc. lifted its holdings in Roivant Sciences by 15.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company’s stock worth $24,553,000 after purchasing an additional 324,764 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Roivant Sciences by 1.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company’s stock worth $24,678,000 after purchasing an additional 34,341 shares during the last quarter. American Century Companies Inc. lifted its holdings in Roivant Sciences by 1.9% during the 2nd quarter. American Century Companies Inc. now owns 89,625 shares of the company’s stock worth $1,010,000 after purchasing an additional 1,689 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in Roivant Sciences by 149.9% during the 2nd quarter. Russell Investments Group Ltd. now owns 11,467 shares of the company’s stock worth $129,000 after purchasing an additional 6,879 shares during the last quarter. Finally, M&T Bank Corp raised its holdings in Roivant Sciences by 10.2% in the 2nd quarter. M&T Bank Corp now owns 12,802 shares of the company’s stock valued at $144,000 after acquiring an additional 1,181 shares in the last quarter. 64.76% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO Matthew Gline sold 289,774 shares of Roivant Sciences stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $29.16, for a total value of $8,449,809.84. Following the transaction, the chief executive officer owned 16,736,116 shares in the company, valued at approximately $488,025,142.56. This trade represents a 1.70% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Jennifer Humes sold 13,538 shares of Roivant Sciences stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $28.37, for a total value of $384,073.06. Following the completion of the transaction, the chief accounting officer owned 84,191 shares in the company, valued at approximately $2,388,498.67. The trade was a 13.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 945,173 shares of company stock worth $27,654,456. 10.80% of the stock is currently owned by company insiders.

Roivant Sciences Price Performance

Shares of NASDAQ ROIV opened at $28.58 on Monday. The stock has a market capitalization of $20.56 billion, a PE ratio of -47.63 and a beta of 1.13. The business has a fifty day moving average price of $28.76 and a two-hundred day moving average price of $25.71. Roivant Sciences Ltd. has a fifty-two week low of $10.70 and a fifty-two week high of $32.79.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings data on Wednesday, May 20th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.57. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.The firm had revenue of $2.52 million during the quarter, compared to analysts’ expectations of $3.41 million. During the same period in the previous year, the firm earned ($0.29) EPS. On average, equities analysts expect that Roivant Sciences Ltd. will post -1.83 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on ROIV. HC Wainwright reaffirmed a “buy” rating and issued a $34.00 price objective on shares of Roivant Sciences in a report on Thursday, May 21st. Citigroup lifted their price objective on Roivant Sciences from $35.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, May 21st. Jefferies Financial Group reaffirmed a “buy” rating on shares of Roivant Sciences in a report on Tuesday, March 3rd. Weiss Ratings cut Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Finally, Sanford C. Bernstein began coverage on Roivant Sciences in a report on Friday, March 20th. They issued an “outperform” rating and a $35.00 price objective for the company. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Roivant Sciences currently has an average rating of “Moderate Buy” and an average price target of $33.59.

Roivant Sciences Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.